Pfizer/BioNTech bid for booster doses premature, more data needed - experts

Pfizer Inc's push for health regulators to authorise a third dose of its Covid-19 shot is not yet backed by evidence, despite the fast-spreading Delta variant, vaccine experts said.

Pfizer and German partner BioNTech SE said last week that they will ask US and European regulators within weeks to authorise a booster dose due to an increased risk of infection after six months.

The companies did not share the data showing...